Abstract
Patients with anti-glomerular basement membrane (anti-GBM) disease have Type IV collagen antigens in their glomerular and alveolar basement membranes. GN or alveolar bleeding develops quickly. Genetically vulnerable people may be activated by environmental factors. There isn't enough evidence to indicate a causal relationship between SARS- cov-2 and COVID-19. One in ten crescentic kidney disease patients has anti-GBM sickness. Early identification of circulating antibodies, increased awareness of rare and challenging clinical manifestations, and immunosuppressive and plasma exchange therapy have improved patients' prognoses. Anti-GBM disease is rare, but new medications and treatments are coming.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
